Investors - Press Releases
Tabula Rasa HealthCare and OneOme Combine Powerful Precision Medication Tools to Improve Medication Safety, Efficacy and Adherence
The partnership will combine OneOme's RightMed® Test and Interpretation Solutions with the deep pharmacy science of TRHC's medication decision support tool MedWise®. The introduction of MedWise increases the value of traditional PGx testing and interpretation services by considering the impact that external factors, such as other medications and certain imflammatory diseases, have on the expression of genes. It also allows PGx results to inform the safety of an entire medication regimen, going far beyond the traditional single drug-gene pair assessment, a property unique to MedWise®. Such synergy will help create better outcomes for patients and when patients experience better health outcomes, patients, providers and payors see more value for their healthcare investment.
PGx analysis provides important clinical insights into specific genes that may affect how a patient's body interacts with certain medications. Inherited variances in these genes can affect how a patient's body metabolizes, transports or responds to medication. In many instances, these variances can help clinicians inform prescribing decisions that may improve patient care and reduce adverse drug events – for example medication selection or dosing adjustments. However, several factors may influence the accuracy of genomic predicted drug response and influence how a body interacts with medications. TRHC's MedWise provides clinicians with more clarity on how certain diseases and other medications can influence drug response than a PGx analysis alone.
According to TRHC Chief Scientific Officer and CEO of
"We are excited to partner with a forward-looking organization like
"OneOme's pharmacogenomic testing services have undergone the scrutiny of Tabula Rasa's
OneOme offers stakeholders across the healthcare industry high-quality, end-to-end solutions for implementing pharmacogenomics in patient care – from individual testing to population-level analytics to laboratory software support. Co-founded by
This press release includes forward-looking statements that we believe to be reasonable as of today's date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "should," and similar expressions. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption "Risk Factors" in our most recent annual report on Form 10-K, filed with the
View original content to download multimedia:http://www.prnewswire.com/news-releases/tabula-rasa-healthcare-and-oneome-combine-powerful-precision-medication-tools-to-improve-medication-safety-efficacy-and-adherence-301269306.html
TRHC Media Contact, Anthony Mirenda, firstname.lastname@example.org, 908-380-2143; TRHC Investors, Frank Sparacino, email@example.com, 866.648.2767